IMMU-31. PNOC007: H3.3K27M SPECIFIC PEPTIDE VACCINE COMBINED WITH POLY-ICLC FOR THE TREATMENT OF NEWLY DIAGNOSED HLA-A2+ H3.3K27M DIFFUSE MIDLINE GLIOMAS (DMG)

OBJECTIVE: To assess safety and efficacy within a multi-center trial the H3.3K27M specific peptide vaccine with poly-ICLC in HLA-A02.01(+) patients diagnosed with H3.3K27M(+) DMGs. METHODS: After focal radiation therapy, participants 3–21 years of age were enrolled into two strata. Stratum A: newly...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Neuro Oncol
Main Authors: Mueller, Sabine, Taitt, Jared, Bonner, Erin, Lulla, Rishi, Goldman, Stewart, Banerjee, Anu, Chi, Susan, Whipple, Nicholas S, Crawford, John, Gauvain, Karen, Nazemi, Kellie, Watchmaker, Payal, Nejo, Takahide, Okada, Kaori, Butterfield, Lisa H, Nazarian, Javad, Villaneuva-Meyer, Javier, Molinaro, Annette M, Prados, Michael, Okada, Hideho
פורמט: Artigo
שפה:Inglês
יצא לאור: Oxford University Press 2020
נושאים:
Immunotherapy
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC7715716/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa222.385
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים